NEOS - Neos Therapeutics, Inc.
| Previous Close | 1.4800 |
| Open | 1.4700 |
| Bid | 1.4300 x 800 |
| Ask | 1.5800 x 1400 |
| Day's Range | 1.4700 - 1.5050 |
| 52 Week Range | 1.1300 - 3.6200 |
| Volume | 573,706 |
| Avg. Volume | 150,442 |
| Market Cap | 74M |
| Beta (5Y Monthly) | 0.97 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4770 |
| Earnings Date | Nov 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.75 |
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 8-Nov-19 1:30pm GMT
Q3 2019 Neos Therapeutics Inc Earnings Call
- GlobeNewswire
Neos Therapeutics Reports Third Quarter 2019 Financial Results
DALLAS and FORT WORTH, Texas, Nov. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- GlobeNewswire
Neos Therapeutics to Host Third Quarter 2019 Financial and Operating Results Conference Call on November 8, 2019
DALLAS and FORT WORTH, Texas, Nov. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- Simply Wall St.
What Kind Of Share Price Volatility Should You Expect For Neos Therapeutics, Inc. (NASDAQ:NEOS)?
If you're interested in Neos Therapeutics, Inc. (NASDAQ:NEOS), then you might want to consider its beta (a measure of...
- GlobeNewswire
Neos Therapeutics to Present at Cantor Fitzgerald Global Healthcare Conference
DALLAS and FORT WORTH, Texas, Sept. 25, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- GlobeNewswire
Neos Therapeutics to Present at Two Upcoming September Conferences
DALLAS and FORT WORTH, Texas, Aug. 29, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery.
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 8-Aug-19 12:30pm GMT
Q2 2019 Neos Therapeutics Inc Earnings Call
- Zacks
Neos Therapeutics (NEOS) Reports Q2 Loss, Misses Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 50.00% and -6.33%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Neos Therapeutics Reports Second Quarter 2019 Financial Results
– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage.
- GlobeNewswire
Neos Therapeutics to Host Second Quarter 2019 Financial and Operating Results Conference Call on August 8th, 2019
DALLAS and FORT WORTH, Texas, Aug. 01, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
Acer Therapeutics Inc. (ACER) receives a Complete Response Letter from the FDA regarding its new drug application for Edsivo for the treatment of vascular Ehlers-Danlos syndrome.
- GlobeNewswire
Neos Therapeutics to Present at Two Upcoming June Conferences
DALLAS and FORT WORTH, Texas, June 12, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire
Neos Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
DALLAS and FORT WORTH, Texas, May 30, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Neos Therapeutics Enters Oversold Territory
Neos Therapeutics has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Neos Therapeutics Inc Earnings Call
- Zacks
Neos Therapeutics (NEOS) Reports Q1 Loss, Tops Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of 31.82% and 3.06%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press
Neos Therapeutics: 1Q Earnings Snapshot
The Grand Prairie, Texas-based company said it had a loss of 15 cents per share. The pharmaceutical company posted revenue of $14.6 million in the period. The company's shares closed at $2.08. A year ago, ...
- GlobeNewswire
Neos Therapeutics Reports First Quarter 2019 Financial Results
DALLAS and FORT WORTH, Texas, May 09, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- GlobeNewswire
Neos Therapeutics to Host First Quarter 2019 Financial and Operating Results Conference Call on May 9th, 2019
DALLAS and FORT WORTH, Texas, May 02, 2019 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing.
- Zacks
Neos Therapeutics (NEOS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Neos Therapeutics (NEOS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Implied Volatility Surging for Neos Therapeutics (NEOS) Stock Options
Investors need to pay close attention to Neos Therapeutics (NEOS) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of NEOS earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Neos Therapeutics Inc Earnings Call
- GuruFocus.com
Neos Therapeutics Inc (NEOS) Files 10-K for the Fiscal Year Ended on December 31, 2018
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder using its drug delivery technologies. Warning! GuruFocus has detected 1 Warning Sign with NEOS. For the last quarter Neos Therapeutics Inc reported a revenue of $15.4 million, compared with the revenue of $7.11 million during the same period a year ago.
